China Medical Technologies goes FISHing
This article was originally published in Clinica
Executive Summary
China Medical Technologies has acquired a fluorescent in situ hybridisation (FISH) business with the aim of developing the technology for diagnostic DNA testing. The Beijing-based firm, which hitherto has focused on enhanced chemiluminescence immunoassay (ECLIA) diagnostics and high intensity focused ultrasound (HIFU) technology, says it hopes to commercialise tests for prenatal and postnatal disorders, as well as for various cancers, in the near term.